Profile
ADMS ZTS HLN TAK TEVA VTRS
Company Name Adamas Pharmaceuticals, Inc. Zoetis Inc. Haleon plc Takeda Pharmaceutical Company Limited Teva Pharmaceutical Industries Limited Viatris Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic
Market Cap - $79.84B $43.93B $42.26B $19.40B $15.82B
Employees 0.14K 14.10K 25.41K 49.28K 37.00K 32.00K
CEO Mr. Neil McFarlane Ms. Kristin C. Peck Mr. Brian James McNamara Mr. Christophe Weber Mr. Richard D. Francis Mr. Scott Andrew Smith Ph.D.
Ratings
ADMS ZTS HLN TAK TEVA VTRS
Quant Rating Score 3 3 3 3 1 3
Quant Rating Neutral Neutral Neutral Neutral Strong Sell Neutral
Trading
ADMS ZTS HLN TAK TEVA VTRS
Last Close $8.22 $176.96 $9.65 $13.38 $17.12 $13.37
High 52 $8.22 $199.94 $10.69 $15.08 $18.96 $13.53
Low 52 $8.22 $145.54 $8.01 $12.6 $10.44 $10.05
Price vs. 52 Week High 0 % -11.49 % -9.73 % -11.27 % -9.7 % -1.18 %
Price vs. 52 Week Low 0 % 21.59 % 20.47 % 6.19 % 63.98 % 33.03 %
Total Return
ADMS ZTS HLN TAK TEVA VTRS
1 Month Return 0 % -6.37 % -2.53 % -3.46 % -7.01 % 15.76 %
3 Month Return 0 % -2.18 % -2.53 % -11.27 % -7.76 % 13.69 %
6 Month Return 0 % 3.55 % 14.07 % 2.76 % 2.15 % 26.97 %
9 Month Return 0 % -10.27 % 14.74 % -8.48 % 32.82 % -1.18 %
YTD Return 0 % -10.34 % 17.25 % -6.24 % 63.98 % 23.45 %
1 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
ADMS ZTS HLN TAK TEVA VTRS
Dividend Yield Percentage (TTM) - 0.98 % 1.62 % 4.75 % - 3.62 %
Dividend Paid and Capex Coverage Ration (TTM) - 2.1 % - 1.29 % 5.06 % 2.39 %
Dividend Per Share (TTM) - 1.73 % 0.06 % 0.63 % - 0.48 %
Payout Ratio (TTM) - 31.44 % - 101.62 % - -65.15 %
Growth
ADMS ZTS HLN TAK TEVA VTRS
Asset Growth -25.98 % -4.28 % -2.18 % 8.25 % -1.2 % -4.67 %
Gross Profit Growth 38.83 % 3.7 % 5.85 % -16.6 % 9.64 % -0.9 %
Revenue Growth 36.28 % 5.74 % 4.09 % 5.87 % 6.16 % -5.14 %
Revenue 3 Year 8264.85 % 31.98 % 13.9 % 33.13 % -6.92 % -35.32 %
Revenue 5 Year 1901.43 % 53.64 % 32.87 % 149.89 % -23.33 % -41.73 %
Revenue 10 Year -46.28 % 103.1 % 32.87 % 154.38 % -40.82 % -26.57 %
EBIT Growth 52.12 % 6.27 % 37.26 % 7.34 % -84.52 % -52.55 %
Net Income Growth 45.43 % 10.88 % -1.04 % -54.56 % 76.24 % -97.37 %
Net Income 3 Yeari Growth Per Share 58.85 % 47.55 % -8.67 % -61.74 % 86.29 % 104.09 %
Net Income 5 Yeari Growth Per Share 42.93 % 71.94 % 59.66 % 62.27 % 76.28 % -93.3 %
Net Income 10 Yeari Growth Per Share -187.49 % 404.24 % 59.66 % 36.33 % -133.42 % -97.12 %
Operating Income Growth 52.12 % 6.27 % 37.26 % 7.34 % -84.52 % -52.55 %
Operating Cash Flow Growth (CFG) 37.23 % 23.06 % -16.48 % -34.47 % -13.96 % -5.18 %
Operating 3 Year CFG 51.33 % 14.12 % 22.08 % -36.76 % 10.09 % 13.84 %
Operating 5 Year CFG 44.68 % 37.69 % 118.54 % 139.61 % -48.98 % -48.37 %
Operating 10 Year CFG -126.38 % 274.61 % 118.54 % 335.67 % -67.94 % -16.8 %
EPS Growth 57.11 % 12.64 % - -54.92 % 76.42 % -97.08 %
EPS Diluted Growth 57.11 % 12.92 % - -54.86 % 76.42 % -97.08 %
Book Value Per Share -4304.47 % 15.25 % 1.35 % 13.54 % -7.25 % -1.92 %
Share Holder 3 Year Equity Growth Per Share -148.48 % 36.7 % -36.6 % 40.38 % -26.74 % -55.34 %
Share Holder 5 Year Equity Growth Per Share -122.15 % 139.55 % -39.41 % 73.27 % -53.44 % -27.35 %
Share Holder 10 Year Equity Growth Per Share -371.92 % 476.36 % -39.41 % 197.1 % -74.76 % 128.81 %
Dividend Per Share Growth - 15.15 % -85.58 % 1.95 % - -0.06 %
Dividend 3 Year Growth Per Share - 87.76 % -83.69 % 1.19 % - -
Dividend 5 Year Growth Per Share - 198.29 % -66.42 % 146.94 % -100 % -
Dividend 10 Year Growth Per Share - 665.58 % -66.42 % 103.93 % -100 % -
Debt Growth 1.76 % -15.91 % -9.43 % 24.67 % -6.53 % -5.93 %
Free Cash Flow Growth 37.24 % 22.25 % -20.06 % -53.54 % -19.19 % -7.35 %
Updated On 31 Dec 2020 31 Dec 2023 31 Dec 2023 31 Mar 2024 31 Dec 2023 31 Dec 2023
Profitability
ADMS ZTS HLN TAK TEVA VTRS
Gross Profit Margin TTM 97.26 % 68.87 % 59.91 % 62.47 % 49.87 % 40.26 %
Return on Assets TTM -47.82 % 16.93 % 3.26 % 1.99 % -2.38 % -1.97 %
Return on Equity TTM 225.69 % 47.99 % 6.54 % 4.04 % -14.58 % -4.43 %
Return on Capital Employed TTM -51.86 % 26.64 % 7.22 % 5.27 % 7.66 % -0.71 %
Net Income Per EBT TTM 100 % 79.65 % 65.38 % 109.03 % 175.89 % 92.81 %
EBT Per Ebit TTM 129.98 % 90.51 % 82.95 % 41.38 % -26.34 % 359.67 %
EBIT Per Revenue TTM -59.31 % 36.83 % 17.82 % 14.14 % 12.76 % -1.76 %
Cash Flow To Debt Ratio TTM -39.02 % 44.8 % - 17.01 % 13 % 13.05 %
Receivables Turnover TTM 8.01 6.49 5.27 6.3 4.85 4.04
Payables Turnover TTM 0.95 7.05 1.25 4.13 3.55 7.23
Inventory Turnover TTM 0.28 1.18 3.09 1.41 2.13 2.2
Fixed Asset Turnover TTM 902.01 % 259.93 % 604.62 % 240.84 % 278.05 % 561.67 %
Asset Turnover TTM 62.04 % 63.75 % 33.71 % 31.2 % 40.19 % 33.6 %
Operating Cash Flow Per Share TTM -1.44 6.5 - 545.34 2.18 1.93
Free Cash Flow Per Share TTM -1.44 5.1 - 309.43 1.75 1.6
Cash Per Share TTM 237.05 % 378.45 % 5.72 % 57513.46 % 292.94 % 157.41 %
Operating Cash Flow Sales Ratio TTM -68.1 % 32.18 % - 18.9 % 14.71 % 15.29 %
Free Cash Flow Operating Cash Flow Ratio TTM 100 % 78.37 % - 56.74 % 80.23 % 83.19 %
Cash Flow Coverage Ratios TTM -39.02 % 44.8 % - 17.01 % 13 % 13.05 %
Price To Free Cash Flows Ratio TTM - 34.59 - 13.38 9.8 8.27
Price To Operating Cash Flows Ratio TTM -5.7 27.21 - 3.77 7.86 6.88
Price Cash Flow Ratio TTM -5.7 27.21 - 3.77 7.86 6.88
Income Statement (TTM)
ADMS ZTS HLN TAK TEVA VTRS
Revenue $0.07B $8.54B $11.3B $4263.76B $15.85B $15.43B
Gross Profit $0.07B $5.83B $6.96B $2321.31B $7.65B $6.44B
Gross Profit Ratio 97.26% 68.28% 61.6% 54.44% 48.25% 41.74%
EBITDA $-0.04B $3.69B $2.35B $900.33B $4.33B $3.52B
Net Income $-0.06B $2.34B $1.05B $144.07B $-0.56B $0.05B
EPS Diluted -1.63 5.07 0.11 91.16 -0.5 0.05
Balance Sheet (MRQ)
ADMS ZTS HLN TAK TEVA VTRS
Long Term Debt $0.13B $6.75B $8.95B $5029.93B $18.48B $16.35B
Total Liabilities $0.17B $9.3B $17.33B $7834.79B $35.35B $27.22B
Total Equity $-0.05B $4.99B $16.73B $7274.01B $8.13B $20.47B
Total Investments $0.01B $0.02B $0.07B $683.22B $0.01B $1.33B
Total Debt $0.13B $6.76B $9.46B $5463.39B $20.15B $18.37B
Total Assets $0.12B $14.29B $34.06B $15108.79B $43.48B $47.69B
Cash Flow Statement (TTM)
ADMS ZTS HLN TAK TEVA VTRS
Net Income $-0.06B $2.34B $1.05B $144.07B $-0.62B $0.05B
Inventory $-0B $-0.36B $-0.13B $-115.74B $0B $-0.61B
Dividends Paid $0B $-0.69B $-0.39B $-287.19B $0B $-0.58B
Operating Cash Flow $-0.05B $2.35B $1.72B $640.32B $1.37B $2.8B
Capital Expenditure $0B $-0.73B $-0.34B $-480.73B $-0.53B $-0.47B
Related Stocks
Ticker Name Price
ACB Aurora Cannabis Inc. 4.34
ACOR Acorda Therapeutics, Inc. 0.661
ACRX AcelRx Pharmaceuticals, Inc. 0.86
ADMP Adamis Pharmaceuticals Corporation 0.775
AERI Aerie Pharmaceuticals, Inc. 15.25
AGRX Agile Therapeutics, Inc. 1.51
AKAN Akanda Corp. 1.36
ALIM Alimera Sciences, Inc. 5.54
ALVO Alvotech 11.99
ALVOW Alvotech 3
AMPH Amphastar Pharmaceuticals, Inc. 45.46
AMRX Amneal Pharmaceuticals, Inc. 8.39
AMYT Amryt Pharma plc 14.7
ANIP ANI Pharmaceuticals, Inc. 56.91
AQST Aquestive Therapeutics, Inc. 4.56
ASRT Assertio Holdings, Inc. 0.9408
ATNX Athenex, Inc. 0.2031
AVDL Avadel Pharmaceuticals plc 11.66
AYTU Aytu BioPharma, Inc. 1.63
BDSI BioDelivery Sciences International, Inc. 5.59
ETFs With Exposure to ADMS
Ticker ETF Name Weight Percentage Price
IEIH iShares Evolved U.S. Innovative Healthcare ETF 0 34.1348
JKJ iShares Morningstar Small-Cap ETF 0.01 231.193
JKL iShares Morningstar Small-Cap Value ETF 0.01 172.726
Unlock